Shots:

• Sorrento receives the US FDA’s clearance to proceed P-I clinical study of STI-1499 (COVI-GUARD) in hospitalized COVID-19 patients. The company receives the FDA’s notice to proceed the patient enrollment
• The trial is anticipated to enroll rapidly and is expected to be followed by large trials targeting a potential EUA submission as early as before the end of 2020. STI-1499 has demonstrated 100% in vitro neutralizing effect against SARS-CoV-2 in preclinical studies
• The highest proposed dose (200mg/patient) in P-I study is a lower dose than currently being tested for other known SARS-CoV-2 targeted Abs or Ab cocktails in studies. Sorrento has initiated cGMP manufacturing to produce 50-000 doses in anticipation of a EUA

­ Ref: Sorrento | Image: Euractive